Tag Archives: Seattle Genetics

William Blair Believes Seattle Genetics (NASDAQ: SGEN) Still Has Room to Grow

William Blair analyst Andy Hsieh reiterated a Buy rating on Seattle Genetics (SGEN – Research Report) on September 18. The company’s shares closed last Friday at $200.93, close to its 52-week high of $213.94. According to TipRanks.com, Hsieh is a

J.P. Morgan Remains a Buy on Seattle Genetics (SGEN)

In a report issued on September 14, Cory Kasimov from J.P. Morgan maintained a Buy rating on Seattle Genetics (SGEN – Research Report). The company’s shares closed last Wednesday at $177.36, close to its 52-week high of $187.99. According to

The President & CEO of Seattle Genetics is Exercising Options

Yesterday it was reported that the President & CEO of Seattle Genetics (SGEN – Research Report), Clay Siegall, exercised options to buy 10,299 SGEN shares at $19.41 a share, for a total transaction value of $200K. Following this transaction Clay

William Blair Keeps a Buy Rating on Seattle Genetics (SGEN)

In a report issued on June 30, Andy Hsieh from William Blair reiterated a Buy rating on Seattle Genetics (SGEN – Research Report). The company’s shares closed last Thursday at $169.53, close to its 52-week high of $175.64. According to

Analysts Offer Insights on Healthcare Companies: Seattle Genetics (NASDAQ: SGEN) and Adverum Biotechnologies (NASDAQ: ADVM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seattle Genetics (SGEN – Research Report) and Adverum Biotechnologies (ADVM – Research Report) with bullish sentiments. Seattle Genetics (SGEN) Leerink Partners analyst

Oppenheimer Gives a Buy Rating to Seattle Genetics (SGEN)

Oppenheimer analyst Jay Olson assigned a Buy rating to Seattle Genetics (SGEN – Research Report) today and set a price target of $175.00. The company’s shares closed last Friday at $157.21, close to its 52-week high of $168.10. According to